Greek trademarks committee rules GSK and GMK are dissimilar

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

Greek trademarks committee rules GSK and GMK are dissimilar

Sponsored by

patrinos-logo.png
Trademark Registration Concept

Evangelia Sioumala of Patrinos & Kilimiris suggests some of the reasoning applied in a decision by the Greek Trademarks Administrative Committee is not in line with settled EU case law

In a recent opposition brought before the Greek Trademarks Administrative Committee (TAC), which is the competent body to decide on oppositions, the TAC considered whether a trademark, below right, seeking registration in classes 5 and 10 is confusingly similar to an earlier trademark, below left, registered in the same classes.

Patrinos.JPG

In its judgment in January 2024, the TAC made reference to settled EU case law; according to which, the overall assessment of the likelihood of confusion must be based on the overall impression given by the marks being compared, bearing in mind, inter alia, their distinctive and dominant elements (C-342/97, Section 18, and C-251/95, Section 22).

Nevertheless, even though the TAC found that the dominant wordsof the trademarks compared (“GSK” and “GMK”) are almost identical in that they consist of three letters, two of which are identical and reproduced in the same order, it concluded that they are not confusingly similar, as the addition of the word “medical” and a cross to the contested trademark suffice to exclude the likelihood of confusion.

Apparent points of divergence with settled EU case law

The ruling does not seem to be in line with settled EU case law; according to which, the difference in a single letter does not constitute a visual and aural difference in marks consisting of only three letters, two out of three of which are identical and in the same order (T-388/00, Sections 66–71).

Furthermore, by ruling that the addition of the word “medical” differentiates the trademarks, the decision contradicted settled EU case law; according to which, the word “medi” or “medical” is not capable of distinguishing goods in the pharmaceutical sector. In addition, the meaning of the word is immediately perceptible to the Greek consumer. The decision also ignored the fact that the presence of a cross is commonplace in the health sector and has become established for the identification of medical products.

With regard to the similarity of the products, although the TAC stated that both trademarks covered products in classes 5 and 10, it concluded that the opponent company operates in the field of medicines and vaccines, while the applicant markets medical devices, thus they are two undertakings with different activities and geographical coverage. The above reasoning is contrary to settled case law that geographical origin is not relevant for the finding of similarity of goods or services.

Finally, the TAC ruled that due to the nature of the products concerned (pharmaceuticals), the degree of attention of the relevant public is high, again contradicting settled case law (T-323/14, Section 77, and C-342/97, Section 18) that the relevant public’s level of attention being high is not, in any event, sufficient to rule out the likelihood of confusion.

The decision can be appealed, and it remains to be seen whether the above reasoning of the TAC will survive a more thorough examination by the higher competent body.

more from across site and SHARED ros bottom lb

More from across our site

The IP services provider is targeting further expansion as cost and efficiency pressures push law firms and in-house teams to rethink how they manage global portfolios
Two experienced UPC practitioners join the UK IP boutique’s growing German operation, with further recruitment planned as the firm expands in Europe
The Australian IP firm is taking on bigger rivals in Southeast Asia, betting that agility and transparent pricing can help it stand out
The firm has brought in former Weil IP leaders Doug Lumish and Jeff Homrig as it looks to deepen its patent, trade secrets and ITC bench
Bird & Bird helps GSK score a major injunction as the battle to become the UPC’s busiest division tightens, and overall filings reach a new monthly high
CEO Annette Bach explains how the Danish IP consultancy plans to build on its 65% profit growth while keeping external investment off the table for now
Belgian attorneys have revived fax systems to protect clients’ filing rights, while uncertainty over exposed patent data has left firms struggling to answer questions about the breach
In his first interview since leaving Weil Gotshal & Manges, Chris Henry explains why he returned to Latham and how he plans to bolster its tech disputes offering
As GTA VI underlines the extraordinary value of gaming franchises, lawyers at Clifford Chance say investors need to know the IP behind their next deal can deliver the growth they are paying for
As ‘big law’ invests in IP litigation, trial firms are emerging as a valuable source of seasoned courtroom talent
Gift this article